RxDoctor Payments Data

Ellis Charles, MD

Psychiatry · East Orange, NJNPI 1013046341

Payments from drug & device makers

$2,679in general payments, 2019–2025

Across 147 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$202
  • Sunovion Pharmaceuticals Inc.$175
  • Johnson & Johnson$142
  • Alkermes, Inc.$91
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$72
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$2,679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,679 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$8,607
Medicare patients
17
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl34$49,196
XanaxAlprazolam11$20,711
RexultiBrexpiprazole12$19,031
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl40$7,233
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,049
Risperidone OdtRisperidone35$6,198
Lurasidone Hcl53$3,487
Alprazolam374$2,716
Quetiapine Fumarate147$1,592
Quetiapine Fumarate ErQuetiapine Fumarate36$938
Clonazepam96$904
Zolpidem Tartrate122$742
Omega-3 Acid Ethyl Esters23$709
Chlorpromazine Hcl12$599
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,915$49,19634 claims
Otsuka America Pharmaceutical, Inc.Rexulti$202$19,03112 claims
Indivior Inc.Suboxone$14$7,04913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →